Proposal by Japan, U.S., Europe and the three pharmaceutical organizations: Joint Proposal for the Formulation of a "Framework Policy" and a "Growth Strategy
May 16, 2022
Japan Pharmaceutical Manufacturers Association (JPMA)
Pharmaceutical Research and Manufacturers of America (PhRMA)
European Federation of Pharmaceutical Industries and Associations (EFPIA Japan)
The Japan Pharmaceutical Manufacturers Association (JPMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and the European Federation of Pharmaceutical Industries and Associations (EFPIA) have compiled the following joint proposal as a unified view of the pharmaceutical industry for the "Framework Policy" and "Growth Strategy" to be developed in June.
Background
- In order to protect the health of the people and maintain a vibrant social economy, an environment in which the public has access to innovative new drugs and vaccines is necessary.
- To this end, we must ensure the attractiveness and competitive advantage of the Japanese market, and continue and develop R&D investment that attracts innovation.
- The following actions should be taken as part of the government's innovation strategy to achieve rapid access to medicines and economic growth at the same time.
Proposals for the Kotto Policy and Growth Strategy
- Promote the establishment of a "drug discovery innovation ecosystem" to deliver innovative new medicines as part of the national strategy
- Activate strategic dialogue between the public and private sectors and promote the establishment of KPIs and their evaluation to realize the "Pharmaceutical Industry Vision 2021
- Improvement and review of the R&D and regulatory environment to encourage continuous investment in the Japanese market
-
Maintaining a drug pricing system that is transparent, predictable, and encourages innovation, and a drug price level for new drugs during the patent period
Organization Overview
Japan Pharmaceutical Manufacturers Association, Inc.
Founded in 1968, the Pharmaceutical Manufacturers Association of Japan (PMAJ) is a voluntary association of 73 R&D-oriented pharmaceutical companies (as of April 1, 2022) that has contributed to global healthcare through the development of innovative new drugs for ethical drugs under the motto "realization of patient-participatory medicine.
The Pharmaceutical Manufacturers Association of Japan (PMAJ) is engaged in a multifaceted program of activities to solve various problems common to the pharmaceutical industry, to deepen understanding of pharmaceuticals, and to promote international collaboration. In addition, PhRMA is committed to the healthy development of the pharmaceutical industry, particularly by strengthening its policy development and advocacy activities, addressing internationalization, and enhancing its public relations structure.
Pharmaceutical Research and Manufacturers of America (PhRMA)
PhRMA represents the leading R&D-oriented biopharmaceutical companies worldwide. Member companies strive to discover and develop new medicines so that patients can live longer, healthier, and more active lives. Member companies have invested more than $1 trillion in new drug research and development since 2000 and an estimated $91.1 billion in 2020 alone.
European Federation of Pharmaceutical Industries and Associations (EFPIA Japan)
Established in April 2002, EFPIA Japan has 23 European R&D-oriented pharmaceutical companies operating in Japan, and the total sales of the member companies in 2020 will account for approximately 23% of the total sales of the Japanese pharmaceutical market, EFPIA Japan's mission is "to contribute to Japanese healthcare and patients through the early introduction of innovative medicines and vaccines.
Documents
For inquiries, please contact
Japan Pharmaceutical Manufacturers Association (JPMA) Public Relations Department
- Phone
- 03-3241-0374
- Inquiry Form
- https://www.jpma.or.jp/inquiry/
Public Relations Office of the Pharmaceutical Research and Manufacturers of America (PhRMA) (in Japan Counselors, Inc.)
- Phone
- 03-3291-0118
European Federation of Pharmaceutical Industries and Associations (EFPIA Japan) Public Relations Committee
- Contact person
- Bayer Holding K.K. Yuko Kidoguchi
- Phone
- 03-6266-7757